Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 4/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589038 | 0.83 | GLS (0.37) | GLSHCAR2KEAP1NFE2L2PRKCA | |
| SCHEMBL3589034 | 0.83 | GLS (0.37) | GLSHCAR2KEAP1NFE2L2PRKCA | |
| SCHEMBL8775651 | 0.81 | GLS (0.33) | GLSGLANPSR1 | |
| SCHEMBL797085 | 0.81 | GLS (0.33) | GLSGLANPSR1 | |
| SCHEMBL797083 | 0.81 | GLS (0.33) | GLSGLANPSR1 | |
| SCHEMBL8775656 | 0.81 | GLS (0.33) | GLSGLANPSR1 | |
| SCHEMBL17225897 | 0.76 | ALDH1A1 (0.38) | GLS | |
| SCHEMBL1623008 | 0.73 | GLS (0.47) | GLSGLANPSR1 | |
| SCHEMBL18916559 | 0.73 | GLS (0.47) | GLSGLANPSR1 | |
| SCHEMBL1623010 | 0.73 | GLS (0.47) | GLSGLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | GLS 431/4885NR3C1 1088/4885HCAR2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.